Ranking Year:
# | Company Name | Region | Tech Topics | Total |
---|
1 | ![]() STARTUP | Noord-Holland, Netherlands | Internet of Things,Application interface,Asset tracking, ...[+2] | market report: 4 |
2 | ![]() STARTUP | Oost-Vlaanderen, Belgium | Wireless,Internet of Things,Information technology consulting, ...[+2] | market report: 4 |
3 | ![]() UNICORN | Software,Computer hardware,Medical equipment, ...[+2] | market report: 3 | |
4 | ![]() STARTUP | Île-de-France, France | Medicine,Pharmacy and Therapeutics,Immune system, ...[+2] | market report: 3 |
5 | ![]() STARTUP | Biology,Cell therapy,Gene, ...[+2] | market report: 3 | |
6 | ![]() STARTUP | Alberta, Canada | Health care,Biopharmaceutical,Specific immunity, ...[+2] | market report: 3 |
7 | ![]() STARTUP | Synthetic biology,Health care,Fidaxomicin, ...[+2] | market report: 3 | |
8 | ![]() STARTUP | Drug discovery,Biotechnology,Medical equipment, ...[+2] | market report: 3 | |
9 | ![]() STARTUP | Immunotherapy,Health care,Cancer, ...[+2] | market report: 3 | |
10 | ![]() STARTUP | Medicine,Blood Disorder,Blindness, ...[+2] | market report: 3 | |
11 | ![]() STARTUP | Diagnostic test,Health care,Molecular medicine, ...[+2] | market report: 3 | |
12 | ![]() STARTUP | Biotechnology,G protein,Membrane protein, ...[+2] | market report: 3 | |
13 | ![]() STARTUP | Genomics,Health care,Cancer, ...[+2] | market report: 3 | |
14 | ![]() STARTUP | Biotechnology,Health care,Pharmacy and Therapeutics, ...[+2] | market report: 3 | |
15 | ![]() STARTUP | Dublin, Ireland | Intellectual property,Genomics,Biotechnology, ...[+2] | market report: 3 |
16 | ![]() STARTUP | Immunotherapy,Clinical trial,Medicine, ...[+2] | market report: 2 | |
17 | ![]() STARTUP | Performance management,Health care,Software, ...[+2] | market report: 2 | |
18 | ![]() STARTUP | Biology,Medicine,Neuroscience, ...[+2] | market report: 2 | |
19 | ![]() STARTUP | Software,Nutrition,Biotechnology, ...[+2] | market report: 2 | |
20 | ![]() STARTUP | Software,Drug discovery,Material Design, ...[+2] | market report: 2 |